MLYS — Mineralys Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $1.00bn
- $802.20m
- 24
- 12
- 92
- 37
Annual balance sheet for Mineralys Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1.41 | 10.6 | 110 | 237 | 198 |
| Prepaid Expenses | |||||
| Total Current Assets | 1.47 | 11.1 | 113 | 249 | 205 |
| Net Property, Plant And Equipment | — | — | — | — | 0.053 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 1.49 | 11.1 | 114 | 252 | 206 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5.08 | 5.05 | 8.07 | 10.5 | 14.6 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 5.08 | 5.05 | 8.07 | 10.5 | 14.6 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -3.6 | 6.07 | 106 | 241 | 191 |
| Total Liabilities & Shareholders' Equity | 1.49 | 11.1 | 114 | 252 | 206 |
| Total Common Shares Outstanding |